Literature DB >> 2583859

IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma.

A Erroi1, M Sironi, F Chiaffarino, Z G Chen, M Mengozzi, A Mantovani.   

Abstract

Our study was designed to investigate the production of interleukin-1 (IL-1) and IL-6 in tumor-associated macrophages (TAM) isolated from ascites (18 cases) or solid (7 cases) human ovarian carcinoma. These are pleiotropic monokines which, in addition to affecting proliferation and differentiation of lymphocytes, act on various targets, including vascular cells and liver, and may therefore be involved in the pathogenesis of certain manifestations of malignancy. IL-1 was measured by the thymocyte co-stimulator assay, under conditions in which IL-6 was inactive, and, in 8 cases, by radioimmunoassay (RIA). IL-6 was measured as hybridoma growth factor (HGF) on the 7TD1 cell line. TAM did not release appreciable levels of IL-1 spontaneously and, upon LPS stimulation, were poor producers of this monokine compared to blood monocytes. In contrast, TAM supernatants contained a high level of HGF in the absence of deliberate stimulation, and exposure to LPS either did not affect or further augmented production of this monokine. HGF activity of TAM supernatants was completely blocked by anti-IL-6 antibodies. Ascites fluid from 8 ovarian-carcinoma patients contained high levels of HGF activity, blocked by anti-IL-6 antibodies. Thus, TAM exhibit a dissociation in their capacity to release the functionally related monokines IL-1 and IL-6. IL-6 produced by TAM may account for the elevation of liver-derived acute-phase proteins associated with malignancy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583859     DOI: 10.1002/ijc.2910440508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

Review 1.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions.

Authors:  Brian C Ward; Sandra Kavalukas; Jamie Brugnano; Adrian Barbul; Alyssa Panitch
Journal:  J Surg Res       Date:  2011-02-23       Impact factor: 2.192

3.  IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.

Authors:  H Yanagawa; S Sone; M Munekata; S Atagi; A Nii; T Ogura
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Tumoricidal effect of human macrophage-colony-stimulating factor against human-ovarian-carcinoma-bearing athymic mice and its therapeutic effect when combined with cisplatin.

Authors:  T Adachi; H Mano; Y Shinohara; T Nakanishi; T Suzuki; K Ino; N Kato; T Okamoto; A Nawa; S Goto
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

5.  Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.

Authors:  Kamisha T Woolery; Patricia A Kruk
Journal:  Obstet Gynecol Int       Date:  2011-06-26

6.  Prostate cancer cells undergoing ER stress in vitro and in vivo activate transcription of pro-inflammatory cytokines.

Authors:  Navin R Mahadevan; Antonio Fernandez; Jeffrey J Rodvold; Gonzalo Almanza; Maurizio Zanetti
Journal:  J Inflamm Res       Date:  2010-08-20

7.  Epithelial ovarian cancer: a cytokine propelled disease?

Authors:  S Malik; F Balkwill
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

8.  Interleukin-1 beta and interleukin-6 release by peripheral blood monocytes in head and neck cancer.

Authors:  O Gallo; A M Gori; M Attanasio; F Martini; B Giusti; M Boddi; E Gallina; O Fini; R Abbate
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

9.  Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines.

Authors:  Saxon Selvey; Larisa M Haupt; Erik W Thompson; Klaus I Matthaei; Michael G Irving; Lyn R Griffiths
Journal:  BMC Cancer       Date:  2004-07-25       Impact factor: 4.430

10.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.